eISSN 2329-0358


Non-immunefactors in chronic rejection. Is there a role for hypolipemic drugs?

Leszek Paczek, Marta BiIl, Janusz Wyzgal, Liliana Gradowska, Zbigniew Galazka, Zbigniew Gaciong

Ann Transplant 1997; 2(2): 65-69

ID: 497163

Published: 1997-06-13

The high prevalence of hypercholesterolemia in kidney transplant recipients probably contributes to the high cardiovascular mortality in these patients and may be a factor contributing to the progression of renal failure. We randomized 42 renal allograft recipients to receive low dose (20 mg) lovastatin or placebo for 32 weeks. All patients had stable graft function (serum creatinine level

Keywords: Kidney Transplantation, lovastatin, lovastatin